The past, present and future of renin-angiotensin aldosterone system inhibition.
Publication
, Journal Article
Mentz, RJ; Bakris, GL; Waeber, B; McMurray, JJV; Gheorghiade, M; Ruilope, LM; Maggioni, AP; Swedberg, K; Piña, IL; Fiuzat, M; O'Connor, CM ...
Published in: Int J Cardiol
September 1, 2013
The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Int J Cardiol
DOI
EISSN
1874-1754
Publication Date
September 1, 2013
Volume
167
Issue
5
Start / End Page
1677 / 1687
Location
Netherlands
Related Subject Headings
- Renin-Angiotensin System
- Hypertension
- Humans
- Heart Failure
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- Antihypertensive Agents
- Animals
- Angiotensin-Converting Enzyme Inhibitors
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Mentz, R. J., Bakris, G. L., Waeber, B., McMurray, J. J. V., Gheorghiade, M., Ruilope, L. M., … Pitt, B. (2013). The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol, 167(5), 1677–1687. https://doi.org/10.1016/j.ijcard.2012.10.007
Mentz, Robert J., George L. Bakris, Bernard Waeber, John J. V. McMurray, Mihai Gheorghiade, Luis M. Ruilope, Aldo P. Maggioni, et al. “The past, present and future of renin-angiotensin aldosterone system inhibition.” Int J Cardiol 167, no. 5 (September 1, 2013): 1677–87. https://doi.org/10.1016/j.ijcard.2012.10.007.
Mentz RJ, Bakris GL, Waeber B, McMurray JJV, Gheorghiade M, Ruilope LM, et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 1;167(5):1677–87.
Mentz, Robert J., et al. “The past, present and future of renin-angiotensin aldosterone system inhibition.” Int J Cardiol, vol. 167, no. 5, Sept. 2013, pp. 1677–87. Pubmed, doi:10.1016/j.ijcard.2012.10.007.
Mentz RJ, Bakris GL, Waeber B, McMurray JJV, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Piña IL, Fiuzat M, O’Connor CM, Zannad F, Pitt B. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 1;167(5):1677–1687.
Published In
Int J Cardiol
DOI
EISSN
1874-1754
Publication Date
September 1, 2013
Volume
167
Issue
5
Start / End Page
1677 / 1687
Location
Netherlands
Related Subject Headings
- Renin-Angiotensin System
- Hypertension
- Humans
- Heart Failure
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- Antihypertensive Agents
- Animals
- Angiotensin-Converting Enzyme Inhibitors
- 3201 Cardiovascular medicine and haematology